Edition:
United States

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

4.05USD
17 Oct 2018
Change (% chg)

-- (--)
Prev Close
$4.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
89,978
52-wk High
$5.13
52-wk Low
$1.79

Latest Key Developments (Source: Significant Developments)

MEI Pharma And Beigene Announce Clinical Collaboration
Thursday, 11 Oct 2018 06:00am EDT 

Oct 11 (Reuters) - Beigene Ltd <6160.HK>::MEI PHARMA AND BEIGENE ANNOUNCE CLINICAL COLLABORATION TO EVALUATE ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES.MEI PHARMA INC - STUDY COSTS WILL BE SHARED EQUALLY BY PARTIES, AND MEI WILL SUPPLY ME-401 AND BEIGENE WILL SUPPLY ZANUBRUTINIB.MEI PHARMA INC - UNDER TERMS OF CLINICAL COLLABORATION AGREEMENT, MEI WILL AMEND ITS ONGOING PHASE 1B TRIAL.MEI PHARMA INC - WILL RETAIN FULL COMMERCIAL RIGHTS FOR ME-401 & BEIGENE WILL RETAIN FULL COMMERCIAL RIGHTS FOR ZANUBRUTINIB.MEI PHARMA - AMENDMENT OF ONGOING PHASE 1B TRIAL TO INCLUDE EVALUATION OF ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES.  Full Article

MEI Pharma Says Selling Stockholders May Offer And Sell Up To 49.5 Mln Shares Of Co's Common Stock
Wednesday, 6 Jun 2018 05:13pm EDT 

June 6 (Reuters) - MEI Pharma Inc ::MEI PHARMA INC SAYS SELLING STOCKHOLDERS MAY OFFER AND SELL UP TO 49.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency
Thursday, 11 Jan 2018 03:00am EST 

Jan 11 (Reuters) - Mei Pharma Inc ::HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML).  Full Article

MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib
Monday, 8 Jan 2018 09:00am EST 

Jan 8 (Reuters) - MEI Pharma Inc ::MEI PHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CDK INHIBITOR VORUCICLIB.MEI PHARMA INC - LOOK FORWARD TO ADVANCING VORUCICLIB THROUGH CLINIC IN Q2 OF 2018.  Full Article

Mei Pharma enters into at-market equity offering sales agreement
Wednesday, 8 Nov 2017 08:48am EST 

Nov 8 (Reuters) - Mei Pharma Inc :On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​.Pursuant to sales agreement co may sell, from time to time, an aggregate of up to $30 million of common stock - SEC filing.  Full Article

BRIEF-MEI Pharma And Helsinn Announce Positive Results In Myelodysplastic Syndrome Trial

* MEI PHARMA AND HELSINN GROUP ANNOUNCE SUCCESSFUL INTERIM ANALYSIS OF PRACINOSTAT/AZACITIDINE PHASE 2 COMBINATION STUDY IN HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS